Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.48 |
| ▸ | INSR | P06213 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598499 | 0.94 | CHEK1 (0.57) | CHEK1IRAK4INSRITKCCNC | |
| SCHEMBL20598607 | 0.92 | CHEK1 (0.55) | CHEK1IRAK4 | |
| SCHEMBL20598527 | 0.89 | CHEK1 (0.57) | CHEK1IRAK4 | |
| SCHEMBL20598346 | 0.87 | CHEK1 (0.60) | CHEK1IRAK4 | |
| SCHEMBL20598300 | 0.86 | CHEK1 (0.54) | CHEK1IRAK4 | |
| SCHEMBL20598045 | 0.86 | CHEK1 (0.54) | CHEK1IRAK4SRPK1 | |
| SCHEMBL20598308 | 0.86 | CHEK1 (0.55) | CHEK1IRAK4CSF1R | |
| SCHEMBL20598587 | 0.85 | CSF1R (0.49) | WDR5CSF1R | |
| SCHEMBL20597981 | 0.85 | IRAK4 (0.66) | CHEK1IRAK4INSRITKWDR5 | |
| SCHEMBL20598108 | 0.85 | CHEK1 (0.57) | CHEK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032642-B | Kinase inhibitors and methods of making and using the same | 里格尔药品股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | claimed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | claimed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | claimed |
| EP-3645525-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | Rigel Pharmaceuticals, Inc. (US) | 2020-05-06 | — | — | EP | claimed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | claimed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | claimed |
| CN-111032642-B | Kinase inhibitors and methods of making and using the same | 里格尔药品股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CHEK1 147/4885IRAK4 4/4885INSR 839/4885 |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CHEK1 147/4885IRAK4 4/4885INSR 839/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | CHEK1 161/4885IRAK4 4/4885INSR 689/4885 |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CHEK1 147/4885IRAK4 4/4885INSR 839/4885 |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | CHEK1 148/4885IRAK4 4/4885INSR 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.